To evaluate the efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ASCO Abstracts, ESMO Abstracts, Wanfang Database, CNKI were searched. Eligible studies were the randomized clinical trials (RCTs) that compared the efficacy and safety profile of adding vandetanib to chemotherapy with single chemotherapy in patients with advanced NSCLC. The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicities. All meta-analysis were performed using Review Manager 5.1. The fixed-effect model weighted by the Mantel-Haenszel method was used. When considerable heterogeneity was found (p<0.1, or I2>50%), further analysis (subgroup analysis, sensitivity analysis or random-effect model) was performed to identify potential cause.
Results reported from 5 RCTs involving 2284 patients were included in the analysis. Compared to chemotherapy alone, the addition of vandetanib resulted in a significant longer PFS (HR 0.79 [0.72–0.87], p<0.00001) and a higher ORR (RR 1.75 [1.43–2.15], p<0.00001), but failed to show advantage on OS (HR 0.96 [0.87–1.06], p = 0.44).
Vandetanib has activity in NSCLC. Identification of predictive biomarkers is warranted in future trials to select a subset of patients with advanced NSCLC who may benefit from vandetanib.
Citation: Tian W, Ding W, Kim S, Zheng L, Zhang L, et al. (2013) Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS ONE 8(7): e67929. doi:10.1371/journal.pone.0067929
Editor: Jian-Xin Gao, Shanghai Jiao Tong University School of Medicine, China
Received: December 21, 2012; Accepted: May 23, 2013; Published: July 4, 2013
Copyright: © 2013 Tian et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by the National Natural Science Foundation of China (81274142, 30300139), the Key Project of Shanghai Municipal Education Commission (07zz43), the Natural Science Foundation of Science and Technology Commission of Shanghai Municipality (11ZR1423400). M.P. was partly supported by the Jiayan Foundation and the Kaiser Foundation Community Benefit Research Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Lung cancer is the leading cause of cancer death world wide, with approximately 221,130 new cases in the United States in 2011, and 85% were non-small cell lung cancer (NSCLC) . Although platinum-based doublet chemotherapy is the current standard treatment for patients with advanced NSCLC, median survival time has been no more than 10 months .
Agents targeting the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling pathways have been clinically validated in patients with advanced NSCLC , . Moreover, EGFR is known to regulate the expression of VEGF, and increased VEGF expression is associated with resistance to EGFR inhibition , . This suggests that a rational therapeutic approach would be combining inhibition of both EGFR and VEGFR signaling by using one single multi-targeted agent without increasing toxicity.
Over the past several years, a number of RCTs have been conducted to investigate the efficacy of adding vandetanib, a once-daily oral anticancer agent that targets VEGFR, EGFR and RET (rearranged during transfection) signaling , , to standard chemotherapy in patients with advanced NSCLC, but with diverse results. It is not clear if this type of combining a targeted therapeutic with chemotherapy provides clinical benefit. Therefore, we have undertaken this meta-analysis to evaluate the available evidence from the relevant RCTs. We will discuss the combined effects, their potential clinical applications and the future directions in this field.
We have collected the eligible trials by searching the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ASCO Abstracts, ESMO Abstracts, Wanfang Database, and CNKI up to October 2012. The Cochrane Highly Sensitive Search Strategy for identifying randomized controlled trials in MEDLINE (Ovid format) was used, as shown in Table 1. And the MEDLINE search strategy was adapted in other databases.
Table 1. Search strategy for MEDLINE (Ovid format) used in this Meta-analysis.doi:10.1371/journal.pone.0067929.t001
All the randomized controlled trials on vandetanib for advanced NSCLC were collected and identified. All reference lists from trials selected by electronic searching to identify further relevant trials were scanned. We have also searched published abstracts from conference proceedings of the American Society for Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).
Eligibility criteria: (1) Type of participants: adults with previously treated or untreated locally advanced (stage IIIB) or metastatic (stage IV) NSCLC. (2) Type of study: studies had to be RCTs comparing the efficacy and safety profile of adding vandetanib to chemotherapy with single chemotherapy in patients with advanced NSCLC. This included the usage of any dosage and schedules of vandetanib as first or second line therapy. (4) Type of publication: All full papers on original data were included. Abstracts or unpublished data were also included if sufficient information on study design, characteristics of participants, interventions and outcomes was available and if full information and final results were confirmed by the first author.
We excluded quasi-randomized studies that were considered to possess insufficient quality. Cross-over studies were excluded in order to assess the overall treatment effect on survival.
Data Extraction and Quality Assessment
Two reviewers independently extracted the data from all included studies. Types of outcome measure included OS, PFS, ORR and toxicities. Only the most frequent events of toxicities were analyzed. We used the methods of summarizing hazard ratios (HRs) of time-to-event data (OS and PFS) provided by Jayne F Tierney et al. . The HRs of time-to-event data (OS and PFS) were extracted from the original studies or accounted from the reported number of events and the corresponding p-value of the log-rank statistics, or by reading off survival curves. We assessed methodological quality of the studies using the Jadad score . We graded each parameter of trial quality as full score (5), high score (≥3), and low score (≤2). We used the name of the first author and the year of publication of the article for identification.
All meta-analysis were performed using Review Manager 5.1. Time-to-event outcomes were compared using a hazard ratio (HR). Dichotomous data were compared using a risk ratio (RR). 95% confidence intervals (CI) were calculated for each estimate and presented in forest plots. Statistical heterogeneity in the results of the trials was assessed by the chi-square test, and expressed by the I2 index, as provided by Higgins et al. . The fixed-effect model weighted by the Mantel-Haenszel method was used. When considerable heterogeneity was found (p<0.1, or I2>50%), further analysis (subgroup analysis, sensitivity analysis or random-effect model) was performed to identify the potential cause.
Our systematic search screened 67 trials, and found 5 publications related to 5 randomized clinical trials (2,284 patients) that compared chemotherapy with or without vandetanib in patients with advanced NSCLC –. These 5 publications included 4 full papers – and 1 conference abstract from ASCO annual meeting . Other potential eligible studies were single-armed or no chemotherapy combination and were therefore excluded. Three phase II , ,  and two phase III ,  trials were included. There was consistency by the reviewers on the identification of studies and the data extraction. The PRISMA Checklist and Flow Diagram for the studies was shown in PRISMA Checklist S1, PRISMA Flow Diagram S1 and Figure 1.
Figure 1. Flow chart for identification and inclusion of trials for this meta-analysis.doi:10.1371/journal.pone.0067929.g001
Characteristics of Included Studies
Characteristics of the included trials were provided in Table 2. And methodological details potentially related to bias of the 5 trials were provided in Table 3. All the 5 trials included illustrations regarding randomization, and 2 of the trials described the detailed methods used for randomization , . Thus, all trials were described as 1 or 2 score based on randomization criteria. All trials described the use of double-blind methodology. Three trials reported detail information of withdrawals , , . All the 5 trials were graded as high score (≥3), and were finally included in the analysis.
Table 2. Characteristics of the five eligible randomized trials in this meta-analysis.doi:10.1371/journal.pone.0067929.t002
Table 3. Methodological details potentially related to bias of the 5 trials.doi:10.1371/journal.pone.0067929.t003
The impact of vandetanib treatment on OS was extracted directly from published data of the 5 included trials. None of the 5 trials reported statistically significant improvement on OS. Meta-analysis showed that, the combination of vandetanib and chemotherapy resulted in no statistically improvement on OS compared with chemotherapy alone (HR 0.96 [0.87–1.06], p = 0.44), without apparent heterogeneity among the studies (p = 0.74, I2 = 0%) (Figure 2). Based on its lack of efficacy on OS in unselected patients, we took further subgroup analyses to define potential groups that may potentially benefit from vandetanib. Exploratory subgroup analysis defined by histology (adenocarcinoma or squamous), sex (male or female), smoking status (smokers or nonsmokers) and therapy line (first or second line therapy), showed similar results, without statistical significance in all the subgroups (Figure 3). When apparent heterogeneity was found in the subgroup of male (I2 = 61%) and smokers (I2 = 74%), random-effect model was used. However, this did not change the final results of the analyses that showed no statistical significances.
Figure 2. Comparison of OS between addition of vandetanib to chemotherapy and chemotherapy alone.doi:10.1371/journal.pone.0067929.g002
Figure 3. Subgroup analyses about the comparison of OS between addition of vandetanib to chemotherapy and chemotherapy alone.doi:10.1371/journal.pone.0067929.g003
Progression Free Survival
All the 5 trials reported outcome of PFS as the primary endpoint. Compared to chemotherapy alone, the combination of vandetanib and chemotherapy resulted in statistically significant improvement on PFS (HR 0.79 [0.72–0.87], p<0.00001), without apparent heterogeneity among the studies (p = 0.92, I2 = 0%) (Figure 4).
Figure 4. Comparison of PFS between addition of vandetanib to chemotherapy and chemotherapy alone.doi:10.1371/journal.pone.0067929.g004
Overall Response Rate
All the 5 trials included in the analysis reported ORR. The combination of vandetanib and chemotherapy significantly improved the ORR (RR 1.75[1.43–2.15], p<0.00001), without apparent heterogeneity among the studies (p = 0.56, I2 = 0%) (Figure 5).
Figure 5. Comparison of ORR between addition of vandetanib to chemotherapy and chemotherapy alone.doi:10.1371/journal.pone.0067929.g005
The outcome of the toxiticies with grade ≥3 for addition of vandetanib to chemotherapy was assessed. Only certain toxicities were consistently described in the 5 articles. We assessed the toxicities of rash and cough mainly caused by targeting EGFR, toxicity of hypertension mainly caused by targeting VEGFR, and other common toxicities occurred in the routine chemotherapy procedure, for example, the diarrhea, nausea, vomiting and anemia. The analysis showed that the grade ≥3 toxicities increased with the addition of vandetanib were rash (RR 6.13 [3.56–10.54], p<0.00001) (p = 0.12, I2 = 49%) and diarrhea (RR 1.61 [1.08–2.40], p = 0.02) (p = 0.23, I2 = 29%). The other toxicities including hypertension (RR 2.83 [0.68–11.69], p = 0.15) (p = 0.54, I2 = 0%), cough (RR 1.01 [0.23–4.48], p = 0.99) (p = 0.46, I2 = 0%), nausea (RR 0.79 [0.31–1.97], p = 0.61) (p = 0.86, I2 = 0%) and vomiting (RR 0.67 [0.28–1.61], p = 0.37) (p = 0.37, I2 = 0%) showed no statistically significant difference. Interestingly, the addition of vandetanib showed a significantly reduced incidence of anemia (RR 0.37 [0.22–0.65], p = 0.0005) (p = 0.17, I2 = 48%) (Figure 6). As QTc prolongation and hemorrhagic events of all grades were also important side effects of TKI targeting VEGFR, we took another analysis of these events as well. The analysis showed that QTc prolongation of all grades increased with the addition of vandetanib (RR 13.03 [3.62–46.89], p<0.0001) (p = 0.82, I2 = 0%). And hemorrhagic events of all grades showed no statistical difference (RR 1.00 [0.81–1.25], p = 0.97) (p = 0.47, I2 = 0%) (Figure 7).
Figure 6. Comparison of grade ≥3 toxicities between addition of vandetanib to chemotherapy and chemotherapy alone.doi:10.1371/journal.pone.0067929.g006
Figure 7. Comparison of QTc prolongation and hemorrhagic events of all grades between addition of vandetanib to chemotherapy and chemotherapy alone.doi:10.1371/journal.pone.0067929.g007
To minimize the potential of publication bias, we used the highly sensitive search strategy to identify the relevant trials. Furthermore, the papers were collected strictly according to the inclusion criteria and publication bias was detected by funnel plot. No apparent publication bias was found in the analysis (Figure 8).
Anticancer therapeutics that specifically target the well-defined signaling pathways important for cancer cell proliferation, invasion and metastasis such as EGFR or VEGFR pathway have shown promising clinical benefit in the treatment of advanced NSCLC , . Furthermore, EGFR is known to regulate the expression of VEGF, and the resistance to tyrosine kinase inhibitors (TKIs) targeting EGFR may be partly associated with a rise in both host and tumor-derived VEGF , . These were the basis for vandetanib, a once-daily oral anticancer agent that targets VEGFR, EGFR and RET signaling, to be combined with chemotherapy for advanced NSCLC in the clinical trials.
Our meta-analysis showed that addition of vandetanib to chemotherapy increased ORR and PFS, but did not improve OS in patients with advanced NSCLC. The results were consistent with the recently published meta-analysis on this subject conducted by Xiao YY et al. . However, the clinical trials included in our analysis are more complete. Because the case volume in the Herbst et al. trial was the largest (occupied approximately 61% among the five RCTs), it led to 68%, 61%, and 57% relative weight in the OS, PFS, and ORR analysis respectively. However, when we performed additional analysis with the subtraction of the Herbst et al. trial data, the overall results remained similar [HR for OS was 0.99 [0.83–1.18], p = 0.88 (p = 0.62, I2 = 0%), HR for PFS was 0.80 [0.68–0.93], p = 0.005 (p = 0.84, I2 = 0%), the RR for ORR was 1.82 (1.34–2.48), p = 0.0001, (p = 0.42, I2 = 0%)]. Therefore, the weight of the Herbst et al. trial did not impact the overall results.
The most frequently reported adverse effect from vandetanib treatment was rash. Side effects caused by vandetanib, and particularly rash, appeared to be more frequent at higher doses. The meta-analysis conducted by Rosen et al. showed that patients who received vandetanib 300 mg had a significantly increased risk of developing all-grade rash in comparison with controls, with a relative risk of 2.43 (95% CI, 1.37–4.29; p = 0.002) . Our meta-analysis showed that 100mg vandetanib could also increase the risk of grade≥3 rash (RR 5.77 [3.32–10.04], p<0.00001). The risk of grade≥3 diarrhea was also increased with the treatment of all dosage vandetanib. But the treatment of 100 mg vandetanib showed no statistically difference (RR 1.50 [0.99–2.26], p = 0.05). The prolongation of QTc by vandetanib requires further post-marketing surveillance.
Interestingly, we found that anemia was mitigated in the combination arm. But definitive conclusions could not be drawn because only 2 trials included in this analysis reported the side effect of anemia , . The explanation of the reducted incidence of anemia treated with vandetanib might be that inhibition of VEGF signaling enhanced erythropoiesis through hypoxia induced factor (HIFa), which had been confirmed in preclinical models . Awareness of these adverse events is critical for clinicians to ensure the best possible clinical benefit.
OS is the gold standard endpoint for clinical improvement in cancer patients. Our meta-analysis showed no improvement on OS, but significant on PFS. The rapid emergence of resistance to vandetanib may be responsible for this discrepancy between OS and PFS, and the ability to overcome drug resistance can obviously change patient outcome outcome and is an important future endeavor. The significant improvement on PFS suggests that vandetanib has activity in NSCLC, and there may be a subgroup of patients who could benefit from this drug which is currently approved by FDA for treating advanced medullary thyroid cancer. Subgroup analyses as defined by histology (adenocarcinoma or squamous), sex (male or female), smoke status (smokers or nonsmokers) and therapy line (first or second line therapy) did not show significant difference in OS. This indicates that there is a critical need for the identification of biomarkers for patients likely to benefit from vandetanib.
Hanrahan et al. found that, patients with low baseline plasma VEGF treated with vandetanib 100 mg/d and docetaxel appeared to have longer PFS and OS compared with those treated with docetaxel alone, whereas patients with high baseline VEGF showed similar treatment outcomes in both arms, but no definitive conclusions on the role of VEGF as a predictive biomarker for benefit from vandetanib could be drawn from this study because of its limitation . However, the prognostic value of baseline plasma VEGF should be evaluated in the future clinical trials.
Furthermore, EGFR and KRAS are the most frequently mutated proto-oncogenes in NSCLC . TKIs targeting EGFR have become important therapeutic options for patients with advanced NSCLC, patients whose tumors harboring a classic EGFR mutation or ALK (anaplastic lymphoma kinase) translocation can substantially benefit from erlotinib or gefitinib –. Whethere or not EGFR and ALK mutations can predict the benefit of vandetanib need to be investigated. Using KRAS mutation status for selecting treatment with EGFR-TKIs remains controversial. A meta-analysis of 22 studies conducted by Mao et al. identified KRAS mutation as a negative predictive biomarker for EGFR-TKI treatment in patients with NSCLC . However, Guan et al. found that though KRAS mutation was a factor for poor prognosis, but not an independent predictor of response to EGFR-TKIs or chemotherapy in patients with lung cancer . The relationship of KRAS mutation status and from the benefit of vandetanib treatment remains to be clarified.
Several limitations exist in this meta-analysis. First, although the publication bias was not found by funnel plots, the small number of the trials limited the power of the analysis. Second, one study we identified was reported in an abstract form only , which made it difficult to extract complete data for analysis, though this study was unlikely to change the overall results because of its small sample size. Furthermore, all the trials included in this analysis used PFS as primary end point. The only trial, conducted by de Boer et al., had a separate survival follow-up analysis .
In conclusion, Vandetanib has shown activity in NSCLC. The identification of predictive biomarkers is warranted in future trials to select a subset of patients with advanced NSCLC who may benefit from vandetanib.
Conceived and designed the experiments: SC WT. Performed the experiments: WT WD. Analyzed the data: WT WD SK XL Lian Zhang. Contributed reagents/materials/analysis tools: WT Leizhen Zheng JG Li Zhang. Wrote the paper: WT SC MP.
- 1. Siegal R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212–236. doi: 10.3322/caac.20121
- 2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543–3551. doi: 10.1200/JCO.2007.15.0375
- 3. Lima AB, Macedo LT, Sasse AD (2011) Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Plos One 6: e22681. doi: 10.1371/journal.pone.0022681
- 4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132. doi: 10.1056/NEJMoa050753
- 5. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, et al. (2006) Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: A rational approach for muti-target anticancer therapy. Ann Oncol 17: vii109–114. doi: 10.1093/annonc/mdl962
- 6. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, et al. (2009) Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15: 3484–3494. doi: 10.1158/1078-0432.CCR-08-2904
- 7. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, et al. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645–4655. doi: 10.1016/j.trstmh.2008.04.039
- 8. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, et al. (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284–7290.
- 9. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16. doi: 10.1186/1745-6215-8-16
- 10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12. doi: 10.1016/0197-2456(95)00134-4
- 11. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560. doi: 10.1136/bmj.327.7414.557
- 12. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, et al. (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-linetreatment for advanced non-small-cell lung cancer. J Clin Oncol 26: 5407–5415. doi: 10.1200/JCO.2008.17.3138
- 13. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, et al. (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treatednon small-cell lung cancer. J Clin Oncol 25: 4270–4277. doi: 10.1200/JCO.2006.10.5122
- 14. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, et al. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advancednon-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619–626. doi: 10.1016/S1470-2045(10)70132-7
- 15. de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, et al. (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lungcancer: a randomized, double-blind phase III trial. J Clin Oncol 29: 1067–1074. doi: 10.1200/JCO.2010.29.5717
- 16. Cesare Gridelli, Silvia Novello, Nicoletta Zilembo, Paolo Foa, Adolfo G Favaretto, et al.. (2012) Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714). J Clin Oncol 30, 2012 (suppl; abstr 7550).
- 17. Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, et al. (2013) Chemotherapy plus Vandetanib or Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of Four Randomised Controlled Trials. Clin Oncol (R Coll Radiol) 25: e7–e15. doi: 10.1016/j.clon.2012.09.005
- 18. Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME (2012) Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 97: 1125–1133. doi: 10.1210/jc.2011-2677
- 19. Fischer C, Carmeliet P, Conway EM (2006) VEGF inhibitors make blood. Nat Med 12: 732–734. doi: 10.1038/nm0706-732
- 20. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, et al. (2009) Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15: 3600–3609. doi: 10.1158/1078-0432.CCR-08-2568
- 21. Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201–205. doi: 10.1513/pats.200809-107LC
- 22. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742. doi: 10.1016/S1470-2045(11)70184-X
- 23. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380–2388. doi: 10.1056/NEJMoa0909530
- 24. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121–128. doi: 10.1016/S1470-2045(09)70364-X
- 25. Mao C, Qiu LX, Liao RY, Du FB, Ding H, et al. (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69: 272–278. doi: 10.1016/j.lungcan.2009.11.020
- 26. Guan JL, Zhong WZ, An SJ, Yang JJ, Su J, et al. (2012) KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy. Ann Surg Oncol 20: 1381–1388. doi: 10.1245/s10434-012-2754-z